

Mentice Secures \$648,410 USD Combined Order for Advanced Simulation Solutions from a Top 20 Global MedTech company

Mentice (publ), Gothenburg, a globally recognized leader in simulation solutions for image-guided interventional therapies, announced today that it has secured a significant order from a top 20 global Med Tech company, a long-standing and valued customer.

The order includes advanced simulation solutions and software development tailored to the fast-growing Electrophysiology (EP) and Structural Heart market to meet the needs of healthcare providers managing complex cardiac conditions. Mentice solutions integrate multiple imaging modalities to enhance interventional procedural outcomes. By combining innovative medical devices, procedural challenges, fluoroscopy, and intracardiac echocardiography (ICE), these solutions optimize market entry strategies and support physician proficiency. They refine visualization skills, standardize training, enhance procedural precision, and improve clinical outcomes. Additionally, they accelerate the adoption of minimally invasive EP therapies globally, meeting the rising demand for advanced, image-guided technologies in key regions.

Frans Venker, CEO of Mentice, commented:

"This collaboration demonstrates our ability to deliver tailored solutions in a high-growth clinical field and highlights the importance simulation technology plays in advancing MedTech innovation. By supporting physician training and procedural adoption, we enable our partners to deliver safer and more effective therapies to patients worldwide."

This partnership solidifies Mentice's reputation as a trusted partner for global healthcare innovators. Through its advanced simulation solutions, Mentice continues to support improved clinical outcomes and facilitate educational initiatives that drive progress in interventional therapies.

The order will be recorded under Mentice's Medical Device Industry division in the first quarter of 2025, with revenues recognized throughout 2025.

Learn more about how this order reflects our commitment to advancing interventional healthcare and supporting sustainable growth. Visit our <u>investor site</u> for insights into our vision, strategy, and ongoing efforts to create value for patients, partners, and stakeholders.

Mentice definition of a Top 20 Medical Technology company can be found here: https://www.beckershospitalreview.com/innovation/100-largest-medtech-companies.html.

For more information, please contact:

Frans Venker, CEO, Mentice

E-post: frans.venker@mentice.com Sweden Mobile +46 735 253 081



About Mentice

Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com

Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC Certified Adviser| FNCA Sweden AB

This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-09 08:00 CET.

Attachments

Mentice Secures \$648,410 USD Combined Order for Advanced Simulation Solutions from a Top 20 Global MedTech company